- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Glecaprevir with pibrentasvir – November 2017
Glecaprevir with pibrentasvir: Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir; Maviret
Last updated
2 March 2018